Article
As the utilization of APPs (nurse practitioners and physician assistants) in rheumatology becomes more prevalent, here are three things to consider if you are thinking about adding an APP to your practice.
All News
Article
December 2025 is focused on advanced practice providers, their impact, education and priorities. In seeking and soliciting the help and advice of leaders in the rheumatology APP world, I have been impressed by APP pride, dedication and passion for what they do.
Article
As a PA with six years of experience in rheumatology and a background in gastroenterology, today I'm discussing the clinical overlap between inflammatory arthritis—particularly psoriatic arthritis and spondyloarthropathies—and inflammatory bowel disease.
Dr. John Cush
Tweet
APP Controversies and Misconceptions
In this Tuesday Night Rheumatology, panelists discuss a range of topics, including APP roles and impact; models of care; independence; seeing new patients and complex cases; and more. Panelists: Daric A. Mueller, PA-C; Lisa Carnago, PhD, https://t.co/t2PssfUNoV
Dr. John Cush
Tweet
APP Pearls “You must assess sleep and mood- without this, even if you control all inflammation, you will not control pain and fatigue!” - Christine Stamatos, NP, DNP, RN
Dr. John Cush
Tweet
Hidden in Plain Sight: IBD
As a PA with six years of experience in rheumatology and a background in gastroenterology, today I'm discussing the clinical overlap between inflammatory arthritis—particularly psoriatic arthritis and spondyloarthropathies—and inflammatory bowel https://t.co/Aatc4jkbpH
Dr. John Cush
Tweet
Disease Activity Criteria for Adult-Onset Still's Disease: EULAR Points to Consider
EULAR has published a "points to consider" (PtCs) guidance on the development of criteria for the assessment of the disease activity in adult-onset Still’s disease (AOSD). https://t.co/3FikFiGgxM
Dr. John Cush
Tweet
Antinuclear Antibodies (ANA)
https://t.co/xERp8kev1T https://t.co/e3psPC7HIl
Dr. John Cush
Tweet
NPs and PAs: Opportunities Outside of the Exam Room
Ben Smith, PA-C, Thomasville, GA, discusses scholarly and leadership opportunities for nurse practitioners and physician assistants, as part of RheumNow's "Mission: APP Partners in Care" campaign during the month of December. https://t.co/Vzx6B1z2xJ
Dr. John Cush
Tweet
“Absence of proof of efficacy does not equal proof of absence of efficacy”
- Arthur Kavanaugh, MD
Dr. John Cush
Tweet
Evaluation of Rheumatic Complaints
https://t.co/cdizOgFqYf https://t.co/YHLAllxpO4
Dr. John Cush
Tweet
FDA has approved nerandomilast (Jascayd) for the treatment of progressive pulmonary fibrosis (PPF) in adults, based on the results of the phase 3 FIBRONEER trial. Nerandomilast is PDE4 inhibitor,, in Oct 2026 it was approved for use in diopathic pulmonary fibrosis (IPF) https://t.co/WVrGj7q7hB
Dr. John Cush
Tweet
2025 Adult Rheumatology Fellowship Match is Strong (Again)
The ACR announced today that 2025 Medicine and Pediatric Specialties Match results show rheumatology fellowship positions continuing to fill at high rates. The Match uses a computerized process to pair applicant and https://t.co/ynP46pEKCa
Dr. John Cush
Tweet
ACR: New Data Highlights Urgent Need to Address Arthritis Burden
New findings from national U.S. surveys reveal the profound impact of arthritis on millions of adults, especially those facing social and economic challenges. These data will be featured in an upcoming issue of https://t.co/3LlNQ3tx90
Dr. John Cush
Tweet
Role of the Nurse in the Care and Management of Rheumatic Diseases - EULAR Review
In 2023, a EULAR subcommittee evaluated the roles of nurses and Advanced Practice Nurses (APNs) in arthritis care per EULAR guidelines. Initially proposed in 2012 and revised in 2018, the scope of https://t.co/w1IOQxcACR
Dr. John Cush
Tweet
Five Fractures You Don’t Want to Miss
In orthopedic practice, missing the wrong fracture can significantly alter a patient’s outcome. Certain injuries may appear subtle on initial imaging yet carry serious consequences if not promptly recognized and managed. https://t.co/zyCRdUkMua
Dr. John Cush
Tweet
Lilly announced phase 3 RCT TRIUMPH-4, where Retatrutide, a new GIP, GLP-1 & glucagon recpt agonist, was given to obese (BMI >35), knee osteoarthritis pts *without diabetes*. Wt loss at 68 wks was 28.7% with reduced WOMAC pain scores of -4.5 points (75.8%) https://t.co/73yIyvwRtL
Dr. John Cush
Tweet
Lyme disease is endemic in Massachusetts. EHR study shows Lyme dz incidence declined from 211 per 100 000 patients in 2012 to 86 per 100 000 in 2024 (P< .001), but this decr. was driven by 1 large practice group implemented a new initiative to reduce Lyme Dx & Rx in pts w/ https://t.co/lMCUA9o4Uc
Dr. John Cush
Tweet
Recent study shows that betw 2018-2023 # of Concierge medicine practices in the USA has increased 78.4% (3,935 to 7,021); mostly in Texas (402), California (387), Florida (352), Georgia (139).” Notably a signif growth of corporate owned practices, increased from 9.2% to https://t.co/nVRPfnwjZv
Dr. John Cush
Tweet
Wolters Kluwer surveyed 203 PAs:
- 62% wish for more clinical experience prior to
- Most adopted AI, majority need more AI training
- 45% prefer title of “physician associate” https://t.co/96Hkh21wSr https://t.co/j7Xep47qMN
